Annexon Inc (ANNX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $747.79M
Last updated: Nov 17, 2026 at 11:05 AM ET
Annexon Inc (ANNX) Earnings: Report Dates and Results
Annexon (ANNX) is confirmed to report earnings on Mar 29, 2027, after the close. In the quarter ended Sep 30, 2026, Annexon reported EPS of -$0.25, above the -$0.28 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ANNX has a confirmed report date of Mar 29, 2027, after the close.
ANNX Earnings Call
The latest ANNX earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 26 quarters below that had an estimate, ANNX beat 13, missed 12 and matched 1. The widest gap in the table came in the quarter ended Sep 30, 2020, when EPS landed 65.71% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.25 | -$0.28 | -$0.30 - -$0.25 | +10.71% | Beat | N/A | 6 | 1 up, 1 down | Nov 9, 2026 |
| Jun 30, 2026 | -$0.28 | -$0.23 | -$0.27 - -$0.22 | -21.74% | Miss | N/A | 6 | 4 up, 0 down | Aug 12, 2026 |
| Mar 31, 2026 | -$0.23 | -$0.30 | -$0.34 - -$0.26 | +23.33% | Beat | N/A | 6 | 0 up, 0 down | May 7, 2026 |
| Dec 31, 2025 | -$0.28 | -$0.32 | -$0.36 - -$0.29 | +12.47% | Beat | N/A | 6 | 2 up, 2 down | Mar 30, 2026 |
| Sep 30, 2025 | -$0.37 | -$0.34 | -$0.35 - -$0.32 | -8.82% | Miss | N/A | 4 | 4 up, 0 down | Nov 10, 2025 |
| Jun 30, 2025 | -$0.34 | -$0.36 | -$0.37 - -$0.35 | +5.56% | Beat | N/A | 4 | 0 up, 3 down | Aug 14, 2025 |
| Mar 31, 2025 | -$0.37 | -$0.29 | -$0.33 - -$0.26 | -27.59% | Miss | N/A | 3 | 0 up, 0 down | May 12, 2025 |
| Dec 31, 2024 | -$0.33 | -$0.29 | -$0.34 - -$0.27 | -12.51% | Miss | N/A | 4 | 3 up, 1 down | Mar 3, 2025 |
| Sep 30, 2024 | -$0.25 | -$0.27 | -$0.31 - -$0.25 | +7.41% | Beat | N/A | 4 | 0 up, 3 down | Nov 14, 2024 |
| Jun 30, 2024 | -$0.23 | -$0.24 | -$0.32 - -$0.19 | +4.17% | Beat | N/A | 8 | 0 up, 0 down | Aug 12, 2024 |
| Mar 31, 2024 | -$0.21 | -$0.35 | -$0.40 - -$0.26 | +40.00% | Beat | N/A | 7 | 0 up, 0 down | May 13, 2024 |
| Dec 31, 2023 | -$0.36 | -$0.44 | -$0.53 - -$0.31 | +18.18% | Beat | N/A | 8 | 3 up, 0 down | Mar 26, 2024 |
| Sep 30, 2023 | -$0.43 | -$0.51 | -$0.58 - -$0.44 | +15.69% | Beat | N/A | 8 | 0 up, 0 down | Nov 13, 2023 |
| Jun 30, 2023 | -$0.47 | -$0.54 | -$0.57 - -$0.50 | +12.96% | Beat | N/A | 8 | 0 up, 0 down | Aug 7, 2023 |
| Mar 31, 2023 | -$0.52 | -$0.52 | -$0.54 - -$0.50 | 0.00% | In line | N/A | 6 | 0 up, 0 down | May 8, 2023 |
| Dec 31, 2022 | -$0.48 | -$0.53 | -$0.57 - -$0.49 | +9.43% | Beat | N/A | 8 | 0 up, 0 down | Mar 6, 2023 |
| Sep 30, 2022 | -$0.51 | -$0.92 | -$0.97 - -$0.71 | +44.57% | Beat | N/A | 8 | 0 up, 0 down | Nov 3, 2022 |
| Jun 30, 2022 | -$0.96 | -$0.95 | -$0.97 - -$0.90 | -1.05% | Miss | N/A | 6 | 0 up, 0 down | Aug 8, 2022 |
| Mar 31, 2022 | -$0.92 | -$1.03 | -$1.08 - -$0.92 | +10.68% | Beat | N/A | 6 | 0 up, 0 down | May 9, 2022 |
| Dec 31, 2021 | -$0.97 | -$0.92 | -$1.00 - -$0.81 | -5.43% | Miss | N/A | 6 | N/A | Mar 1, 2022 |
| Sep 30, 2021 | -$0.93 | -$0.88 | -$0.90 - -$0.86 | -5.68% | Miss | N/A | 5 | N/A | Nov 9, 2021 |
| Jun 30, 2021 | -$0.82 | -$0.68 | -$0.72 - -$0.62 | -20.59% | Miss | N/A | 4 | N/A | Aug 16, 2021 |
| Mar 31, 2021 | -$0.68 | -$0.65 | -$0.66 - -$0.52 | -4.62% | Miss | N/A | 4 | N/A | May 17, 2021 |
| Dec 31, 2020 | -$0.61 | -$0.44 | -$0.47 - -$0.42 | -38.64% | Miss | N/A | 3 | N/A | Mar 25, 2021 |
| Sep 30, 2020 | -$0.58 | -$0.35 | -$0.38 - -$0.31 | -65.71% | Miss | N/A | 3 | N/A | Nov 16, 2020 |
| Jun 30, 2020 | -$28.87 | -$0.53 | -$0.62 - -$0.37 | N/A | N/A | N/A | 3 | N/A | Jul 24, 2020 |
| Mar 31, 2020 | -$3.30 | -$2.13 | N/A | -54.93% | Miss | N/A | N/A | N/A | Jun 3, 2020 |
| Sep 30, 2019 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 6, 2019 |
| Jun 30, 2019 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 18, 2019 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.36, after -$1.02 the year before. It was -$33.47 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.36 | N/A |
| Dec 31, 2024 | -$1.02 | N/A |
| Dec 31, 2023 | -$1.78 | N/A |
| Dec 31, 2022 | -$2.87 | N/A |
| Dec 31, 2021 | -$3.40 | N/A |
| Dec 31, 2020 | -$33.47 | N/A |
Earnings Calls
The only earnings call listed below, 2026Q2 for the period ended Jun 30, 2026, runs about 5,600 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 5,619 | 12 |
2026Q2 Earnings Call
Opening remarks
Douglas Love President and Chief Executive Officer Thank you, operator. Good morning, and welcome, everyone. Earlier this morning, Annexon issued a press release announcing that we have expanded our ARCHER II Phase III trial for vonaprument in geographic atrophy, in a press release announcing key business updates and second quarter financial results. Copies of these press releases are available on the company's website and through our SEC filings. On today's call, we will be making forward-looking statements, including statements relating to the existing clinical data and the therapeutic and commercial potential of our investigational drug candidates. Joining me today are Dr. Jamie Dananberg, our EVP and Chief Medical Officer, and Dr. Lloyd Clark, SVP of Ophthalmology Strategy and Innovation, who will discuss our GBS and GA programs, respectively. I will then close before we open the call for questions, where we will be joined by Dr. Ted Yednock, EVP and Chief Innovation Officer; and Jen Lew, our Chief Financial Officer. Before we turn to the updates, I'd like to briefly frame Annexon's broader opportunity and our excitement about building a leading, fully integrated biotech company, driven by our mission to help millions of people live their best lives. Annexon was founded on discoveries from Stanford University to create a new class of targeted immunotherapies that stop C1q-mediated neuroinflammation at its source with the goal of rapidly and meaningfully preserving and potentially improving function for patients of serious neuroinflammatory diseases of the body, the brain and the eye. Built on more than 2 decades of foundational C1q biology and a highly translational approach in the clinic, we have generated robust, compelling evidence supporting the potential of C1q inhibition across multiple diseases. Indeed, leveraging our pioneering science and our warrior spirit culture to tackle some of the most pressing diseases in our industry, Annexon is the first and only company to successfully conduct fully randomized placebo-controlled trials of GBS, a life-threatening and debilitating disease that is sudden and completely indiscriminate in who it strikes, robbing otherwise healthy people of their normal lives. Annexon is also the first and only company to demonstrate significant vision preservation in a fully randomized, sham-controlled study in geographic atrophy, a mass population disease, irreversible blindness that robs millions of people of their independence. Lastly, Annexon is the first and only company to develop and clinically study an oral small molecule designed to selectively inhibit the classical pathway with the potential to offer those with serious complement-mediated autoimmune conditions a convenient and flexible oral dosing option.
Frequently Asked Questions About ANNX
When is Annexon's next earnings date?
Annexon's next earnings report is confirmed for Mar 29, 2027, after the close.
Did ANNX beat earnings estimates last quarter?
Yes. Annexon reported EPS of -$0.25 for the quarter ended Sep 30, 2026, above the -$0.28 estimate, a 10.71% surprise.
What EPS do analysts expect from ANNX next quarter?
The consensus EPS estimate for Annexon for the quarter ending Dec 31, 2026 is -$0.27 from 13 analysts, with estimates from -$0.29 to -$0.24.
How often does ANNX beat earnings estimates?
Annexon beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -2.32%.
Does ANNX report before or after the market opens?
Annexon is confirmed to report on Mar 29, 2027, after the market closes.
ANNX pages: Overview, Earnings, Forecast, Financials, Competitors